Also, high-risk patients have a higher frequency of mutations in genes such as RUNX1, TP53, and ASXL1, which are molecular genetic markers of high risk for AML, which confirms the prognostic reliability of the risk score assessment. This evidence concerns the gene RUNX1 and acute myeloid leukemia.